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Abstract 
Subunit vaccine formulations are often produced as liquid dispersions through complicated processes. It is 
desirable, however, to have simple, cheap and up-scalable methods to produce nanoparticulate subunit 
vaccines in powder form. Here, a simple single-step spray drying process for production of powder 
cubosome precursors with the model antigen ovalbumin (OVA) and the adjuvant Quil-A is presented. The 
cubosomes were characterized in vitro and evaluated in vivo by subcutaneous and oral administration for 
their potential as a vaccine formulation. Hydrated cubosomes had average particle size of 257±8 nm and 
zeta potential of -18.0±0.6 mV. The powder contained 10.6±0.7 % w/w OVA prior to hydration, of which 
65±1 % was released within the first 20 min in 9.5 mM PBS at pH 7.3, with the remaining OVA gradually 
released over the following 24 h. Immunization with cubosomes resulted in significantly stronger antigen-
specific serum IgG responses (p < 0.01), CD8+ T cell expansion (p < 0.0001) and target T cell killing compared 
to controls when given s.c., and was ineffective orally. This study shows that spray drying is a suitable 
method for producing nanoparticulate vaccine formulations in dry powder form. 
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Introduction  
Immunization through vaccination is the most significant and cost-effective medical contribution to 
public health and disease prevention (Azmi et al., 2014; Foged, 2011). However, many pathogens remain 
the cause of serious health issues in large areas of the world, thus sustaining the need for continued 
vaccine development and administration (Ehreth, 2003; Foged, 2011; Zhao and Leong, 1996). An important 
limitation to the worldwide administration of vaccines is the high costs of manufacturing and distribution. 
Consequently, there is an additional need for developing inexpensive methods of producing vaccines which 
can be distributed at reduced costs (Hill et al., 2016). Vaccines have traditionally been based on live-
attenuated or whole-killed organisms. These have intrinsic immunostimulatory capacity, sufficient to elicit a 
strong immune response. However, due to the present emphasis on safety in vaccines, modern vaccines 
are based on highly purified peptides or proteins referred to as subunit antigens (Azmi et al., 2014; Foged, 
2011). Subunit antigens lack the secondary signals required to elicit a strong immune response and must 
therefore be formulated with adjuvants. Adjuvants are compounds that are delivered together with 
antigens to improve and modulate the immune response to a vaccine (Azmi et al., 2014; Foged, 2011). 
 
The protein ovalbumin (OVA) is often used as a model antigen as it is relatively inexpensive and 
accessible. A wide range of immunopotentiating compounds exist, including bacterial products, aluminum 
salts, immunopotentiating cytokines and natural products such as Quil-A. Quil-A is an inexpensive adjuvant 
obtained by purification of an extract from the bark of the Chilean tree Quillaja saponaria Molina (Kensil et 
al., 1995). It is a Toll-like receptor independent adjuvant composed of a heterogeneous mixture of 
chemically related triterpenoid saponins (Hook and Rades, 2013; Kensil et al., 1995) and has been studied 
widely for use in immune stimulating complexes (Hook and Rades, 2013) or together with delivery systems 
such as liposomes (Demana et al., 2004; Gordon et al., 2012; Rattanapak et al., 2012; White et al., 2006) 
and cubosomes (Gordon et al., 2012; Kojarunchitt et al., 2015; Rattanapak et al., 2012). Quil-A can induce 
strong antibody responses and cytotoxic T cell responses. Cytotoxic T cell responses are necessary for 
protection against intracellular pathogens and in the removal of infected or transformed cells and are often 
difficult to achieve with non-replicating vaccines (Hook and Rades, 2013; Myschik et al., 2008a; White et al., 
2006). Saponins are able to associate with cholesterol in cell membranes and create membrane pores. This 
is proposed to be the principal mechanism for their potentiation of immune responses, although several 
other mechanisms have also been suggested (Gordon et al., 2012; Hook and Rades, 2013; Kersten and 
Crommelin, 2003). Pore formation may allow vaccines to enter the cytosol of antigen presenting cells 
(APCs) thus allowing for cross-presentation of antigen and facilitating cytotoxic T cell mediated immunity 
(Heeg et al., 1991).  
 
Particulate subunit vaccine delivery systems are inherently more immunogenic than their soluble 
counterparts. This has commonly been attributed to an ability to protect the antigen from rapid 
degradation, prolonged antigen presentation, better uptake by antigen presenting cells and physical 
similarity to native pathogens (Foged, 2011; Storni et al., 2005). A wide range of micro- and nano-sized 
colloidal particles have been investigated as delivery systems including polymeric and lipid based particles 
such as emulsions and liposomes (Foged, 2011). Liposomes are dispersions of lamellar liquid crystals 
(lamellar mesophases) forming spherical particles with a lipid bilayer surrounding an aqueous core (Foged, 
2011; Rizwan et al., 2013). This gives liposomes the ability to encapsulate a wide range of bioactive 
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compounds, and liposomes have therefore been studied extensively for vaccine delivery purposes (Foged, 
2011; Rizwan et al., 2013). 
 
Analogous to liposomes, cubosomes are dispersions of the bicontinuous cubic mesophase (Rizwan et al., 
2013). The basic unit of the bicontinuous cubic mesophase is a lipid bilayer, which is contorted into an 
isotropic infinite periodic minimal surface (IPMS) with 3-dimensional long-range order (Hyde, 2001; Spicer 
et al., 2002a). Like the bulk cubic phase, cubosomes are composed of a highly contorted lipid bilayer 
forming a continuous lipid domain and two highly tortuous but non-intersecting water domains. 
Cubosomes therefore have a high lipid content and a large surface area giving them the ability to 
encapsulate a wide range of bioactive compounds (Rizwan et al., 2007; Spicer, 2005). This makes 
cubosomes flexible with regards to the types of antigens and adjuvants they can carry. Rizwan et al. have 
shown that cubosomes allow for a larger amount of encapsulated compound compared to liposomes and 
also provide a more efficient retention of an antigen (Rizwan et al., 2013). Furthermore, cubosomes have 
been shown in vivo to be a promising particulate carrier for vaccines as they effectively promote antigen 
transport into the draining lymph nodes (Liu et al., 2016) and are capable of stimulating a stronger immune 
response than equally adjuvanted liposomes (Rizwan et al., 2013).  
 
Cubosomes are traditionally produced by a top-down approach in which a bulk liquid crystal is mixed 
with polymeric stabilizers in water and disrupted into nanoparticles by use of high-energy input 
fragmentation (Caltagirone et al., 2014; Rizwan et al., 2011; Uyama et al., 2009). These preparation 
methods are laborious and difficult to scale up (Rizwan et al., 2011) and therefore alternative methods for 
preparing cubosomes are highly desirable. The bottom-up approach exploits self-assembly of certain lipids 
dissolved in organic solvent upon dilution in excess water (Rizwan et al., 2011; Spicer, 2003). This approach 
is simple, easy to scale up and avoids the need for high-energy input. However, it can additionally be 
desirable to have the particles in a powder form, which spontaneously forms cubosomes upon rehydration 
(Nielsen et al., 2017; Spicer et al., 2002a). These powders are often referred to as ‘precursors’ and have 
earlier been produced by spray drying (Avachat and Parpani, 2015; Nielsen et al., 2017; Shah et al., 2006; 
Spicer et al., 2002b) or freeze-drying (Bei et al., 2010). Spray dried powder forms of vaccine formulations 
are easy to transport and can provide improved storage stability. They thereby hold the promise to 
circumvent the need for cold-chain storage, which is necessary for the majority of available vaccine 
formulations in order to maintain antigen integrity (Sou et al., 2011). Ohtake et al. reported the successful 
use of spray drying to produce a dry powder formulation of a measles vaccine. Here, the storage stability of 
the powder was improved to 8 weeks at 37˚C compared to 1 week for the commercial lyophilized 
formulation (Ohtake et al., 2010). 
 
Spray drying is a method in which a highly dispersed liquid is brought into contact with a sufficient 
amount of hot air to dry the droplets into particles through evaporation (Ameri and Maa, 2006; Fang and 
Bhandari, 2017). It has the advantage of being a highly versatile, cheap and scalable method and can be 
operated under aseptic conditions (Fang and Bhandari, 2017; Searles and Cherian, 2015). Furthermore, it is 
well suited for drying labile products, as can be essential when producing vaccine formulations (Ameri and 
Maa, 2006; Fang and Bhandari, 2017). In the literature, it is reported that spray drying molten monoolein 
together with aqueous starch resulted in powders, but the mixture was difficult to spray dry as a cubic 
phase is immediately formed upon hydration of monoolein (Spicer et al., 2002a). To solve the problem, 
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Spicer et al. added ethanol as a hydrotrope to dissolve the cubic phase and substituted starch with the 
ethanol-soluble dextran, thus obtaining an emulsion which could easily be spray dried. The addition of 
dextran provided a flowable spray dried powder and helped stabilize the colloidal cubosomes that formed 
spontaneously upon hydration of the powder (Spicer et al., 2002a). In later work, a similar method was 
used to spray dry cubosomes with the incorporation of the protein OVA (Nielsen et al., 2017). However, an 
adjuvant is required in order to obtain a complete vaccine formulation, and was not included in that study.  
 
Cubosomes have previously been studied for their use in parenteral vaccines (Gordon et al., 2012; 
Kojarunchitt et al., 2015; Liu et al., 2016; Rizwan et al., 2013) but their use in oral vaccines has not been 
reported due to concerns of limited stability in the gastro intestinal tract and the induction of an adequate 
immune response. However, they are an appealing option for oral delivery of antigens as cubic phase liquid 
crystals made from monoolein are reported to be biocompatible, biodegradable, bioadhesive (Nielsen et 
al., 1998; Patton and Carey, 1979) and able to increase the oral bioavailability of  poorly soluble drugs (Ali 
et al., 2017). Oral vaccines are desirable for compliance, but more importantly aid mass vaccination by 
easing logistics and avoiding needles, thus eliminating the need for highly trained personnel and improving 
safety especially in developing countries (Azizi et al., 2010; Gebril et al., 2012).  
 
The aim of this study was to provide a simple and scalable method for producing a dry powder subunit 
protein vaccine formulation by spray drying. Cubosomes containing OVA as a model antigen and the 
adjuvant Quil-A were produced, characterized in vitro and then evaluated in vivo in mice by measuring 
humoral and cellular immune responses following  subcutaneous (s.c.)  and oral delivery.  
 
Materials and methods 
Materials 
Dimodan® MO 90/D (monoolein) was kindly donated by Danisco (Grindsted, Denmark). Fluorescein 
isothiocyanate (FITC - isomer I), ovalbumin (Grade VII, from chicken egg white) and dextran (from 
Leuconostoc spp., 40 kDa) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Quil-A was obtained 
from Brenntag Biosector (Frederikssund, Denmark) and phosphate buffered saline (PBS) tablets were 
acquired from Oxoid limited (Basingstoke, England). 5,6-carboxyfluorescein diacetate succinimidyl ester 
(CFSE) and CellTraceTM Violet Cell Proliferation Kit (CTV) were purchased from Molecular Probes® (Eugene, 
OR, USA). Alum (Alu-Gel-S) was purchased from Serva (Heidelberg, Germany). OVA257–264 peptide (SIINFEKL) 
was purchased from Mimotopes (Clayton, Australia). Milli-Q water (Merck Millipore, Darmstadt, Germany) 
was used throughout the study. All other chemicals were of analytical grade and used as received. 100 kDa 
ultrafiltration filters (Amicon Ultra-0.5 with Ultracell 100 membrane) were purchased from Merck Millipore 
(Darmstad, Germany), and Hellma® absorption cuvettes (Suprasil® quartz, 1 mm path length) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). 
 
Mice 
Specific pathogen free 6-8 weeks old male C57BL/6 (B6), OT-I and OT-II mice were obtained from the 
Hercus Taieri Resource Unit, University of Otago, Dunedin, New Zealand. Mice had unlimited access to food 
and water throughout the experiment. All experiments were approved by the Animal Ethics Committee at 
the University of Otago (AEC no. 80-16). 
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Spray drying of cubosome precursors containing OVA and Quil-A 
Cubosome precursors were prepared using monoolein (Dimodan® MO 90/D), and the cubosomes were 
loaded with OVA and Quil-A and stabilized by dextran. Dimodan was dissolved in ethanol (5.33 mg/mL) and 
then mixed 1:3.04 (v/v) with a solution of OVA, Quil-A and dextran in water (0.52, 0.035 and 2.63 mg/mL, 
respectively). The resulting emulsion was stirred for 15 min and then spray dried using a Büchi B-290 mini 
spray dryer (Büchi Labortechnik AG, Flawil, Switzerland) in open-loop configuration with a B-296 
dehumidifier (Büchi Labortechnik AG, Flawil, Switzerland) and a pressure nozzle with a diameter of 1.5 mm. 
Air was utilized as drying gas with the spray drying parameters given in Table 1. Blank particles with dextran 
as well as particles with dextran and either OVA or Quil-A were produced to be used as controls. Following 
completion of the process, spray dried powders were collected and stored in glass vials. Residual moisture 
in the powders was further reduced in a secondary drying step by placing the powders in an oven at 86±2oC 
for 24 h. Afterwards, the powders were stored in a dry environment.  
 
Table 1. Spray drying parameters applied for spray drying of cubosomes 
Feed rate 4.5 mL/min 
Atomizing air flow 667 L/h 
Aspirator rate 100 % 
Inlet temperature 150oC 
Measured outlet temperature 86oC 
 
Internal structure and morphology of cubosomes using SAXS and Cryo-TEM 
The internal structure of hydrated particles dispersed in water was investigated by small angle X-ray 
scattering (SAXS) at the SAXS/WAXS beamline at the Australian Synchrotron, Clayton, Australia (Kirby et al., 
2013). Powders were reconstituted at 50 mg/mL in water using vortex mixing together with four cycles of 3 
min ultrasonication with 2 mm solid glass beads and then loaded into glass capillaries. The X-ray beam had 
an energy of 12 keV (1.03 Å) and the sample was placed 1531 mm from the detector. Diffraction patterns 
were converted to intensity vs q-value plots to enable the identification of relative peak positions and 
corresponding Miller indices, which were then used to identify the space group of the dominant internal 
nanostructure of the sample (Hyde, 2001). The internal structure of dry particles prior to hydration was 
investigated in a similar manner at the Austrian SAXS/WAXS beamline at the synchrotron light source 
ELETTRA (Trieste, Italy).  
The morphology of the hydrated particles containing OVA and Quil-A was further investigated by 
cryogenic transmission electron microscopy (cryo-TEM) using a Tecnai G2 20 TWIN transmission electron 
microscope (FEI, Hillsboro, OR, USA). Particles were reconstituted at 5 mg/mL in water and then prepared 
using a FEI Vitrobot Mark IV under controlled (4oC, 100 % relative humidity) and automated conditions (blot 
time 3 s, blot force 0). 5 µL of sample was deposited on a glow-discharged 300 mesh lacey carbon grid 
(Pelco Lacey, Ted Pella Inc., CA, USA). Excess liquid was removed by blotting and the sample was then 
immediately snap frozen in liquid ethane and kept in liquid nitrogen. Imaging was performed at an 
acceleration voltage of 200 kV with a 4K CCD Eagle digital camera from FEI. 
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Size, zeta potential and stability of cubosomes 
The average particle size (z-average) of hydrated particles was measured by dynamic light scattering 
(DLS) using the photon correlation spectroscopy technique and the zeta potential of the particles was 
investigated using the laser-Doppler electrophoresis method. All measurements were performed using a 
Zetasizer Nano Zs (Malvern Zetasizer, NanoZs Zen 3600, Malvern, UK) equipped with a 633 nm laser and 
173o detection optics at 25oC. Data acquisition and analysis was performed using Malvern DTS v.7.12 
software (Malvern, UK). For size measurements, 1 mg/mL of powders were reconstituted in filtered 9.5 mM 
PBS at pH 7.3 using four cycles of 3 min ultrasonication with glass beads and then measured by DLS after 15 
min. Colloidal stability was investigated by storing the particles at 25oC and measuring particle size after 
0.5, 6 and 24 h. For zeta potential measurements, powders were reconstituted at 1 mg/mL in the same 
manner as for size measurements, but using a filtered 9.5 mM phosphate buffer at pH 7.3. All 
measurements were performed in triplicates of three independent samples. Morphological stability of 
cubosomes with OVA and Quil-A was investigated by periodic SAXS measurements for 26 h of a 50 mg/mL 
cubosomes suspension in PBS at 37oC as described above. 
 
OVA load, encapsulation efficiency and release of OVA from cubosomes 
FITC was conjugated to OVA as described by Könnings et al. (Könnings et al., 2002) and cubosome 
precursors containing FITC-OVA and Quil-A were produced as described above. The load of FITC-OVA in the 
powder was measured by dissolving 0.25 mg/mL of FITC-OVA and Quil-A containing cubosomes in 5 % v/v 
Triton X-100 in 9.5 mM PBS at pH 7.3 immediately before measurements. Standards of FITC-OVA spiked 
into 0.25 mg/mL dissolved Quil-A cubosomes were prepared in the same way as the samples. The 
standards and samples were analyzed by spectrofluorimetry on a VarioskanTM LUX microplate reader 
(ThermoFisher Scientific, Denmark) using 494 and 520 nm as excitation and emission wavelength, 
respectively, and 500 ms of collection time. Standards and samples were prepared in three independent 
replicates with four repeated aliquots of each.  
Encapsulation efficiency and release of OVA from the cubosomes were measured using an ultra-filtration 
method. FITC-OVA and Quil-A containing cubosomes were rehydrated at 0.2 mg/mL in 9.5 mM PBS at pH 
7.3 using four cycles of 3 min ultrasonication with glass beads. Hydrated cubosomes were kept rotating at a 
speed of 150 rpm at 37oC in the dark. Aliquots from four independent samples were taken at 0, 0.5, 1, 2, 4, 
6, 8, 24, 27, 30 and 48 h after hydration and immediately subjected to ultrafiltration through a 100 kDa 
membrane (allowing FITC-OVA to pass but retaining the cubosomes), facilitated by centrifugation at 14,000 
G for 10 min. Filtrates were then collected and stored in the dark until fluorimetric analysis was performed 
in the same way as described above for antigen load. The 0 h time point was used to estimate the 
entrapment of FITC-OVA in the cubosomes. Three independent sets of standards were prepared by spiking 
FITC-OVA into 0.2 mg/mL Quil-A cubosomes in 9.5 mM PBS, pH 7.3, followed by ultrafiltration similar to the 
loaded cubosomes.  
 
Stability of secondary structure of OVA during formulation and storage 
Changes in secondary structure of OVA during cubosome production were investigated by circular 
dichroism (CD). Far-UV CD spectra (190–260 nm) were recorded at 20°C in a 1 mm quartz cuvette on a 
Chirascan CD spectrometer (Applied Photophysics, Leatherhead, UK) equipped with a Peltier thermostated 
cell holder. Ten scans were averaged at 0.5 nm step-size and 0.5 s integration time per point. 
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 Cubosomes were reconstituted to 1 mg/mL with vortex mixing and ultrasonication (as described above) 
in 9.5 mM phosphate buffer, pH 7.3. Cubosome samples from two different batches were measured before 
and after the secondary drying step (24 h at 86oC). For investigation of stability of OVA during storage, the 
CD spectrum was recorded for a sample of OVA and Quil-A cubosomes which had been stored for 6 months 
in dry conditions at room temperature. CD spectra of Quil-A containing cubosomes were subtracted as 
background from the spectra from OVA and Quil-A containing cubosomes. OVA in 9.5 mM phosphate 
buffer at pH 7.3 was used as a control for the native protein and OVA boiled for 2 h was used as a control 
for disruption of secondary structure. Lyophilized OVA was heated to 86±2oC for 24 h and used as control 
for whether the cubosomes stabilize the OVA during the secondary drying step. In all samples, OVA was 
used in a concentration of 0.106 mg/mL.  
 
Immunological Studies 
Cubosomes were stored for 1-2 months at room temperature prior to use for the vaccine study. C57Bl/6 
mice received 2 x 106 naïve OT-I and OT-II  lymphocytes (which have T cell receptors that recognize CD8 and 
CD4 epitopes from OVA (Kojarunchitt et al., 2015)) in 200 µL PBS injected intravenously (i.v.) into the tail 
vein on day -1 (Figure 1). Oral groups received vaccine on days 0, 14 and 28 while s.c. groups received 
vaccine injected into the flank on days 14 and 28. Oral vaccines consisted of spray dried cubosomes with 
100 µg OVA and 6.7 µg Quil-A in a capsule (Torpac size M) or a solution of 100 µg OVA and 6.7 µg Quil-A in 
100 µL PBS. Subcutaneous vaccines used were a solution of cubosomes with 0.67 µg Quil-A in 200 µL PBS 
(no antigen), a solution of 10 µg OVA and 0.67 µg Quil-A either unformulated or in cubosomes in 200 µL 
PBS, or 10 µg OVA in 200 µL alum.  
Four days after the last immunization, mice were injected i.v. with 4 x 106 C57Bl/6 lymphocytes pulsed 
with 10 µg/mL SIINFEKL and labelled with CFSE in combination with 4 x 106 unpulsed lymphocytes labelled 
with CTV. Mice were sacrificed on day 34 and blood, spleens and lymph nodes were collected. 
 
 
Figure 1. Timeline of the in vivo experiment investigating the immune stimulating effects of spray dried 
cubosomes with OVA and Quil-A. 
 
Flow cytometry 
Individual spleens and pooled lymph nodes were processed into single cell suspensions essentially as 
previously described (Myschik et al., 2008a). Aliquots of cells were stained with anti-CD8 (BioLegend®), anti-
CD4, anti-Vα2 and anti-Vβ5 antibodies (BD PharmingenTM) and propidium iodide (BioLegend®). Data was 
acquired on a BD FACSCantoTM II (BD Biosciences) and was analyzed using FlowJo version 10.3 software 
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(Tree Star, Inc.) using the gating strategy shown in Figure S1. The antigen-specific killing of peptide pulsed 
target cells was calculated as  
 % 𝑘𝑘𝑘𝑘𝑘𝑘𝑘𝑘𝑘𝑘𝑘𝑘𝑘𝑘 = �1 − 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑘𝑘𝑝𝑝𝑝𝑝 𝑝𝑝𝑝𝑝𝑘𝑘𝑝𝑝𝑝𝑝𝑝𝑝 𝑐𝑐𝑝𝑝𝑘𝑘𝑘𝑘𝑝𝑝
𝑝𝑝𝑘𝑘𝑝𝑝𝑝𝑝𝑘𝑘𝑝𝑝𝑝𝑝𝑝𝑝 𝑐𝑐𝑝𝑝𝑘𝑘𝑘𝑘𝑝𝑝 � × 100 % (eq. 1) 
 
and normalized to the negative control (cubosomes with Quil-A but without OVA) as 0 %. 
 
Serum IgG levels in vaccinated mice 
Blood samples were left overnight at 4oC to allow clotting and sera were separated by centrifugation at 
9,402 G for 10 min. OVA specific serum IgG was measured by ELISA. High-binding 96 well plates (Corning 
inc. Corning, NY, USA) were coated overnight at 4oC with 100 µL of 10 µg/mL OVA in 50 mM carbonate 
buffer at pH 9.6. Wells were blocked with 150 µL blocking buffer (PBS pH 7.3 with 2 % w/v BSA) for 1 h at 
room temperature and washed 6 times with wash buffer (PBS pH 7.3 with 0.05 % v/v Tween-20). Serum 
samples (diluted 1:100) were added to the first column of well plates, serially diluted across the plate and 
incubated for 2 h at room temperature. The plates were washed and 100 of 225 ng/mL HRP Goat anti-
mouse IgG (BioLegend®) was added to wells and incubated for 1 h at room temperature. Plates were 
washed and 100 µL of substrate reagent solution (Substrate reagent pack, R&D SYSTEMS®, MN, USA) was 
added and incubated at room temperature for 5 min. The reaction was then stopped with 50 µL of 2 M 
H2SO4 and the absorbance was read at 450 nm using a Polarstar Omega Microplate Reader (BMG Labtech, 
Ortenberg, Germany). 
 
Statistics 
All statistical analysis was performed with Prism 7 (GraphPad, San Diego, USA). The experiments were 
performed in 3-4 replicates and the data is presented as mean ± standard deviation (SD). Where relevant, 
statistical significance was determined by unpaired two-sided T-tests, using a significance level of 5 % or by 
ordinary one-way ANOVA and Tukey’s multiple comparisons test. 
 
Results and discussion 
Spray drying of cubosome precursors containing OVA and Quil-A 
One of the best characterized binary systems forming cubic mesophases is the monoolein/water system. 
This system is desirable to use for cubosome production due to the resulting temperature stability and the 
availability of low-cost raw materials (Spicer et al., 2001). Phytantriol has recently been used increasingly as 
cubic phase forming lipid because it offers increased stability and purity, but monoolein was preferred here 
as it is substantially cheaper (Rizwan et al., 2013, 2011). 
 
In this study, powder cubosome precursors containing OVA and/or Quil-A as well as blank particles were 
produced by mixing together solutions of monoolein and dextran with OVA and Quil-A added as applicable, 
followed by spray drying the mixture to obtain a powder. Preliminary studies showed that a monoolein to 
dextran weight ratio of 2:3 provided good stabilization of the spray dried powder without adding 
unnecessary extra bulk. Powder yields from the spray drying process were approximately 75 % for all the 
formulations and white opaque dispersions resulted from rehydration of the powders.  
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Internal structure and morphology of cubosomes  
The monoolein/water system gives rise to two main forms of the bicontinuous cubic phase: The gyroid 
(Ia3d) forms at low hydration and the diamond (Pn3m) forms at high hydration (Spicer et al., 2002a). 
Identification of mesophases is predominantly performed using SAXS in combination with cryo-TEM 
imaging (Hyde, 2001; Rizwan et al., 2007). Therefore, SAXS was used in this study to investigate the bulk 
structural morphology of powders as well as of each dispersion prepared (Figure 2). Hydrated particles 
(Figure 2a) that did not contain OVA (blank and Quil-A containing particles) resulted in SAXS patterns 
characteristic of vesicles, whereas hydrated particles formulated with OVA showed SAXS patterns 
characteristic of the cubic (Pn3m) phase (Bragg peaks at relative positions of √2:√3:√4:√6:√8:√9). 
Cubosomes with OVA and Quil-A and cubosomes with OVA alone had lattice parameters of 98 Å and 95 Å, 
respectively. Interestingly, all dry powders resulted in SAXS patterns without peaks which is characteristic 
of vesicles (Figure 2b). This showed that cubosomes are not formed in the spray drying feed or during the 
spray drying process, but are formed upon rehydration of the powder. In a previous study where a 
liposome-based vaccine was manufactured and then spray dried, the authors reported that optimization of 
both formulation and processing conditions was necessary to stabilize the liposomes through the drying 
process (Ingvarsson et al., 2013). The method presented here skips the particle preparation step prior to 
spray drying and circumvents the need for such optimization since the cubosomes are only formed after 
rehydration of the powder. It thereby offers improved robustness and reduced costs. 
 
Quil-A is a highly surface active compound which interacts with lipid membranes and disrupts these at 
high Quil-A concentrations (Demana et al., 2004). However, it has been reported not to disrupt liposomes 
at 2 % w/w (Quil-A/lipid) (White et al., 2006). For this reason, Quil-A was used at 2 % w/w (Quil-A/lipid) in 
this study and it was found that the addition of Quil-A did not change the morphology of the vesicles and 
cubosomes in the absence and presence of OVA, respectively. The slightly greater lattice parameter in the 
presence of Quil-A could be understood as a slight swelling due to the charge carried by Quil-A as observed 
for other ionic surfactants (Liu et al., 2013). 
 
The structural morphology of hydrated OVA and Quil-A cubosomes was verified by cryo-TEM (Figure 3) 
that showed substructures characteristic of cubosomes (Hyde, 2001). The substructure of blank cubosomes 
was also investigated by cryo-TEM and while cubosomes were found, they were less abundant than in the 
OVA and Quil-A containing samples and instead more vesicles were seen. This could indicate that the lack 
of Pn3m SAXS signal seen from blank cubosomes was a consequence of a too low cubosome concentration 
caused by much of the lipid forming vesicles instead of cubosomes. These data thereby suggest that OVA 
has a stabilizing effect on cubosomes. It is yet to be seen if clinically relevant antigens will also provide this 
effect. However, in a case where it cannot, other polymeric stabilizers such as Poloxamer 407 may be 
added to achieve a similar effect (Spicer et al., 2001).  
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Figure 2. q vs intensity patterns obtained from SAXS measurements of a) dispersions in water of cubosomes 
with no Quil-A or OVA (blank), only Quil-A, only OVA, and OVA and Quil-A. b) Spray dried powders of 
monoolein and dextran with no Quil-A or OVA (blank), only Quil-A, and with OVA and Quil-A. Bragg peaks at 
relative positions of √2:√3:√4:√6:√8:√9 were seen in hydrated particles formulated with OVA as well as 
OVA and Quil-A and are marked on the figure.  
 
 
Figure 3. Representative cryo-TEM images of hydrated cubosomes containing OVA and Quil-A. The particles 
show substructures characteristic of cubosomes. 
 
Size, zeta potential and stability of cubosomes 
The size and surface properties of particulate vaccines affect their function, as reviewed by Bachmann et 
al. (Bachmann and Jennings, 2010). Cubosomes containing OVA and/or Quil-A as well as blanks were 
characterized for their size and polydispersity index (PDI) using DLS. All hydrated particles had average sizes 
in the nano-range with high homogeneity (PDI values between 0.1-0.2) (Table 2). OVA cubosomes had an 
average size of 316±21 nm, whereas blank particles had a size of 134±7 nm. The addition of Quil-A to blank 
particles (Quil-A particles) led to a small but significant (p = 0.0289) decrease in size to 120±3 nm. However, 
the addition of Quil-A to OVA cubosomes (OVA and Quil-A cubosomes) led to a more pronounced and 
significant (p = 0.0104) decrease in size to 257±8 nm. The presence of Quil-A in particles additionally led to 
a reduction of the PDI whether or not OVA was co-formulated. Antigen presenting cells have been reported 
in the literature to process particulates in the size range of 20 nm to 3 µm and there is no clear evidence of 
an ideal size within this range (Bachmann and Jennings, 2010). All particles were hence of a size suited for 
vaccination. 
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The zeta potential of particles is a measure of their surface charge and is often used as an indicator of the 
colloidal stability of the dispersion (Heurtault et al., 2010; Kallerup et al., 2017). It is reported in the 
literature that as a rule of thumb, particles with zeta potential of magnitude greater than 30 mV will be 
colloidally stable and that a zeta potential of approximately 20 mV is indicative of short-term colloidal 
stability. Particles with zeta potential of -5 to 5 mV may be expected to agglomerate quickly (Honary and 
Zahir, 2013). In this study, the zeta potentials of all particles were negative. The zeta potential of blank 
particles was measured to be -43.6±0.4 mV. However, addition of Quil-A and/or OVA reduced the zeta 
potential to approximately -20 mV indicating that the latter formulations will show limited colloidal 
stability. This was investigated further for OVA and Quil-A cubosomes where a dispersion was left to stand 
for 24 h without agitation and the average particle size was measured at various time points. The particle 
size and PDI gradually increased, indicating that the cubosomes were slowly agglomerating (Table 3). The 
difference was significant after 30 min (p = 0.0176), where the particle size had increased to 299±11 nm, 
and after 24 h the size was 451±12 nm. However, as discussed above, this increased size is not likely to be 
of importance for the immune response to the formulation. The morphological stability of cubosomes with 
OVA and Quil-A was also investigated (Figure 4) and it was found that the structure of the cubosomes was 
unchanged for at least 26 h in an aqueous dispersion. Thus, the agglomeration of the cubosomes seems not 
to affect the particle morphology. 
 
Table 2. Size, PDI and zeta potential of particles dispersed in 9.5 mM PBS at pH 7.3 (size and PDI) or 
phosphate buffer at pH 7.3 without added salts (zeta potential) measured by DLS. Data represents mean ± 
SD (n = 3).  
Formulation size (nm) PDI Zeta potential (mV) 
Blank particles  134±7 0.19±0.04 -43.6±0.4 
Particles with Quil-A  120±3 0.11±0.00 -17.0±1.0 
Cubosomes with OVA 316±21 0.23±0.02 -20.9±0.4 
Cubosomes with OVA and Quil-A 257±8 0.11±0.08 -18.0±0.6 
 
Table 3. Colloidal stability in 9.5 mM PBS at pH 7.3 for OVA and Quil-A cubosomes measured over 24 h by 
DLS. Data represents mean ± SD (n = 3).  
Time size (nm) PDI 
0 h 264±11 0.15±0.03 
0.5 h 299±11 0.21±0.02 
6 h 354±12 0.26±0.01 
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24 h 451±12 0.31±0.03 
 
0 . 0 5 0 . 1 0 0 . 1 5 0 . 2 0 0 . 2 5
q  ( Å
- 1
)
In
te
n
s
it
y
 (
a
.u
.)
0  h
2 6  h
 
Figure 4. q vs intensity patterns obtained from SAXS measurements of a dispersion of cubosomes with OVA 
and Quil-A in PBS pH 7.3 at 37oC at 0 and 26 h after reconstitution. Bragg peaks at relative positions of 
√2:√3:√4:√6:√8:√9 were seen at both time points and are marked on the figure. 
 
OVA loading, encapsulation efficiency and release of OVA from cubosomes 
To quantitate the OVA load and release, FITC-labeled OVA was used. The total FITC-OVA content in the 
spray dried powder of OVA and Quil-A cubosome precursors was measured after dissolving the cubosomes. 
The content was found to be 106.0±0.7 µg/mg of FITC-OVA in the bulk powder corresponding to the 
composition of the liquid mixture before spray drying. Vaccines are generally administered by injection s.c. 
or intra-muscularly. However, due to the multitude of benefits offered by oral administration over 
injection, there have been many efforts to allow oral administration of drugs and vaccines (Sahni et al., 
2016). A promising strategy is to pack the vaccine into advanced delivery systems such as microcontainers 
(Amenitsch et al., 1998; Nielsen et al., 2017). The high OVA content in the cubosomes presented here 
makes this formulation well suited for coupling with such administration systems. 
 
The release of FITC-OVA from the OVA and Quil-A cubosomes was measured over 48 h in 9.5 mM PBS, pH 
7.3 (Figure 5). Immediately after reconstitution, 65 % of the loaded OVA was free in solution and then a 
gradual release was observed until all FITC-OVA was released at 24 h. Entrapment efficiency of FITC-OVA in 
the cubosomes was evaluated as the relative amount of FITC-OVA not released during rehydration (a 20 
min process) of the cubosomes and was determined to be 35±1 % (mean ± SD, n = 4). The 65 % FITC-OVA 
measured outside the cubosomes after reconstitution is in contrast to a similar cubosome formulation with 
OVA, where a limited burst release upon hydration of the cubosome precursors was reported (Nielsen et 
al., 2017). Nielsen et al. speculated that the observed burst release was actually not a burst release from 
the particles, but instead dissolution of free OVA in the powder (Nielsen et al., 2017). This notion is 
supported by the lack of a burst release in another study where the cubosomes were not formulated as 
powder, but instead directly as a concentrated suspension of cubosomes (Rizwan et al., 2013). The study 
here and the one presented in the literature (Nielsen et al., 2017) used similar methods to produce the 
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formulations, but in this study a significantly higher OVA concentration was added to the cubosomes. 
Hence, the larger burst release seen in this study is likely to be related to a relatively larger amount of FITC-
OVA present outside the cubosomes in the powder rather than entrapped in or associated to the cubosome 
precursors. Another difference to the work by Nielsen et al. is the addition of Quil-A to the cubosome 
precursors in the current study. Quil-A has previously been reported to reduce the OVA-peptide 
entrapment of cubosomes by a factor of three (Rattanapak et al., 2012) and a similar effect of the addition 
of Quil-A could be speculated to be the case in this study. The addition of Quil-A may also be the 
explanation for the increased release rate of FITC-OVA seen in this study compared to the very slow and 
incomplete release after 4-10 days reported in earlier studies (Nielsen et al., 2017; Rizwan et al., 2013). 
 
Physical linkage of antigen to adjuvant, either by direct interaction of antigen and adjuvant or by 
entrapment, encapsulation or adsorption of antigen and adjuvant to a particle (e.g. liposomes), has been 
widely reported to be important for the immunogenicity of a vaccine as reviewed by Kamath et al (Kamath 
et al., 2012). However, White et al. reported similar levels of antigen specific cytotoxicity after vaccination 
with Quil-A containing liposomes admixed with free antigen as with liposomes containing both antigen and 
Quil-A (White et al., 2006). Physically linking the antigen to the particle/adjuvant or delivery of soluble 
antigen together with particle/adjuvant will therefore likely cause a similar immune response. 
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Figure 5. Release of FITC-OVA from cubosomes (also containing Quil-A) in 9.5 mM PBS at pH 7.3 and 37oC. 
The insert shows the release over the first 8 h. Data are expressed as % released of total OVA content and 
are represented as mean ± SD (n = 4). The aliquots used for the 0 h time-point were taken immediately 
after a 20 min reconstitution process.  
 
Stability of secondary structure of OVA during formulation and storage 
CD of hydrated cubosomes was used to verify preservation of the secondary structure of OVA during 
production and storage. Native OVA and OVA boiled for 2 h were used as controls for preserved and 
changed secondary structure respectively. The CD spectra from both controls were similar to those 
reported in the literature (Hamborg et al., 2013). All cubosome samples showed similar CD patterns to the 
control of native OVA (representative spectra are shown in Figure 6, all spectra are shown in Figure S2) 
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indicating a preserved secondary structure of OVA after both spray drying and the secondary drying step 
(86oC for 24 h), as well as after storage for 6 months at room temperature under dry conditions. Lyophilized 
OVA was also exposed to the secondary drying step and a preserved secondary structure was observed 
(Figure S3) indicating that dry OVA was stable. Preservation of the secondary structure of OVA during spray 
drying of cubosomes may thus be due to the high stability of OVA, but may also result from spray drying 
being a low temperature method with a fast drying step. In the early part of the spray drying process, the 
drying air is hot but the surface of the particles is wet and thus evaporation will cause constant loss of heat 
keeping the droplet temperature much lower than the drying gas temperature. This effect will eventually 
disappear, but at this stage the labile compounds will be dry and the drying gas will have cooled due to the 
preceding heat-loss due to evaporation (Ameri and Maa, 2006). Since OVA on its own is stable during the 
secondary drying step, one may consider whether clinically relevant peptides may be damaged by similar 
treatments. However, the secondary drying step was merely implemented for accurate in vitro 
characterization of the formulations and may be omitted if desired. Additionally, it is worth noting that 
denatured forms of proteins in some cases stimulate stronger immune responses than native forms, 
especially in the case of cell mediated immune responses, and therefore heat-denaturation of the antigen 
might not be undesirable (Speidel et al., 1997). 
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Figure 6. Representative CD spectra of OVA and Quil-A containing cubosomes after spray drying and 
secondary drying at 86oC for 24 h (solid black). The CD spectrum of a control for preserved secondary 
structure (native OVA) is shown in green and for changed secondary structure (OVA boiled for 2 h) is shown 
in red. The concentration of OVA was 106 µg/mL in all measurements. 
 
Serum IgG levels in vaccinated mice 
Antigen specific serum IgG is often used as an indicator of systemic humoral immune reactivity. Mice 
were immunized with cubosomes with OVA and Quil-A, cubosomes without antigen (negative control), 
unformulated OVA and Quil-A, and OVA in alum (positive control) and anti-OVA serum IgG was measured 
(Figure 7). Alum has been used widely as a vaccine adjuvant and is known to be a strong stimulator of 
antibody responses (Oleszycka and Lavelle, 2014). The use of Quil-A in human vaccines has so far been 
limited due to the occurrence of injection site reactions thus making it desirable to use a low dose (Hook 
and Rades, 2013). The cubosomes prepared in this study contained Quil-A as adjuvant at a 1:15 (w/w) ratio 
to OVA giving a low parenteral Quil-A dose of 0.67 µg (Myschik et al., 2008b). Nonetheless, OVA and Quil-A 
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in cubosomes elicited significantly more total antigen-specific serum IgG than alum (p < 0.01) and all other 
controls (p < 0.001), showing that they induce a strong humoral immune response. This dry powder 
cubosome formulation appeared to be equally as effective as cubosomes produced from solution with 
monophosphoryl lipid A (MPL) and imiquimod as adjuvants (Rizwan et al., 2013). However, OVA and Quil-A 
given orally either in PBS or in cubosomes did not elicit an antibody response, thus indicating that a better 
delivery system is needed for oral delivery of cubosomes.  
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Figure 7. OVA specific serum IgG antibody titers. The data are from individual mice from a representative 
experiment of three independent experiments together with mean ± standard deviation (n = 5 
mice/experiment). ** p < 0.01, *** p < 0.001. 
 
Antigen-specific cell expansion assay and in vivo cytotoxicity assay  
Mice received antigen-specific transgenic CD8+ and CD4+ cells from OT-I and OT-II mice by adoptive 
transfer prior to vaccination. OT-I mice have been genetically engineered to express a high proportion of 
CD8+ T cells with a T cell receptor specific for the OVA257-264 peptide and OT-II mice to express CD4+ T cells 
with a T cell receptor specific for the OVA323-339 peptide (Kojarunchitt et al., 2015). To investigate the 
cellular immune response to the cubosomes, expansion of antigen-specific T cells (vα2+ vβ5+) was assessed 6 
days after the last immunization (Figure 8). A significantly greater expansion of CD8+ cells was observed in 
spleens and lymph nodes from mice immunized s.c. with cubosomes with OVA and Quil-A compared to all 
controls (p < 0.001, Figure 8a and Figure 8b). The response to unformulated OVA and Quil-A was 
comparable to that to alum, which is known to be a weak adjuvant for stimulating a cellular response 
(Oleszycka and Lavelle, 2014). This indicates that s.c. administration of cubosomes with Quil-A can 
stimulate a strong cytotoxic T cell immune response important for protection against cytosolic infections. 
Orally administered cubosomes had no effect.  
CD4+ T cell responses are important for activating, improving and controlling immune responses and thus 
an ideal vaccine will elicit a CD4+ T cell response (Rosa et al., 2010). Cubosomes with OVA and Quil-A could 
induce antigen specific CD4+ expansion comparable to alum in both spleens and lymph nodes (Figure 8c and 
Figure 8d). The response was significantly stronger than control without antigen (p < 0.01) but comparable 
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to unformulated OVA and Quil-A. A small CD4+ response was observed from oral unformulated OVA and 
Quil-A, but no response was seen from oral cubosomes. 
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Figure 8. In vivo expansion of transgenic CD8+ cells (a and b) and CD4+ cells (c and d) in spleens (a and c) and 
lymph nodes (b and d). Data in a and c are results from individual mice plus the mean and SD from a 
representative experiment of three independent experiments (n = 5 mice/experiment). Data in b and d are 
pooled data from 4-5 mice in each of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, 
**** p < 0.0001. 
 
The antigen specific cytotoxic T cell response was further investigated through an in vivo cytotoxicity assay 
by measuring the killing of OVA-peptide pulsed cells relative to unpulsed cells (Figure 9). Quil-A has 
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received great interest for its ability to stimulate CD8+ cytotoxic T cell responses (Hook and Rades, 2013). In 
this study, both OVA with alum and OVA in solution with Quil-A resulted in significantly greater target cell 
death than the control without OVA (p < 0.0001). In agreement with the cell expansion data, mice 
immunized with OVA and Quil-A in cubosomes provided the highest level of killing of OVA-labelled target 
cells, with almost total removal of target cells causing saturation of the assay. The assay saturation is likely 
the reason why the cubosomes did not cause significantly more killing than unformulated OVA and Quil-A 
or OVA with alum. When administered orally, unformulated OVA and Quil-A potentially had some effect, 
but this was not significant. Orally administered cubosomes with OVA and Quil-A had no effect which is an 
agreement with the transgenic cell expansion results.  
 
In summary, s.c. administered cubosomes stimulated both humoral and cellular immune responses to OVA 
and this was not seen after oral administration. It is possible that an effect could have been obtained using 
a more advanced oral vaccine delivery system (Davitt and Lavelle, 2015; McHugh et al., 2017). One such 
system is microcontainers presented in the literature (Chirra et al., 2014; Mazzoni et al., 2017; Nielsen et 
al., 2016). These offer protection of their load through the stomach; however, they have limited internal 
volume and therefore limited loading capacity for the formulations they deliver. The stability at room 
temperature and high antigen load of the cubosome powder presented here renders it well suited for 
future application with microcontainers.  
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Figure 9. In vivo killing of adoptively transferred OVA-peptide labelled T cells in spleens. Data shown are 
results from individual mice plus the mean and SD from a representative experiment of three independent 
experiments (n = 5 mice/experiment). *p < 0.05, ***p < 0.001, **** p < 0.0001. 
 
Conclusion 
Dry powder precursors of cubosomes containing the model antigen ovalbumin and the adjuvant Quil-A 
were produced in a simple one-step spray drying process. The powder precursors were stable at room 
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temperature and formed cubosomes in the nanometer-size range upon hydration. These cubosomes 
provided effective vaccination when administrated s.c. in mice but no effect was observed after oral 
administration. Since this vaccine is in a powder form with a high antigen load, it is well suited for 
application with microfabricated administration systems such as microcontainers. 
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